Identifying Therapeutic Targets in Receptor-Negative Cancers

You are reading version 1 of this direction, frozen 2026-10-04. The latest version is version 2.

Version 1 of 297 papers97 conceptsfrozen 2026-10-04

In the era of precision medicine, oncology has largely relied on "molecular handles"—specific receptors or mutated proteins that act as targets for designer drugs. However, a significant subset of aggressive malignancies, most notably triple-negative breast cancer (TNBC), is defined by what it lacks. By definition, TNBC lacks the estrogen, progesterone, and HER2 receptors that standard therapies target. Similarly, "double-negative" prostate cancers and "driver-negative" lung adenocarcinomas lack the genetic triggers that usually guide treatment.

When the front door is locked and there is no keyhole, researchers must find alternative vulnerabilities. This research direction focuses on identifying the "dark matter" of cancer biology: the metabolic dependencies, signaling hijacks, and immune landscapes that allow these receptor-negative cells to thrive.

Exploiting Metabolic Dependencies

When a cancer cell loses its primary growth receptors, it must rewire its internal machinery to sustain its rapid proliferation. This rewiring creates unique metabolic "addictions" that are not present in healthy cells.

One of the most promising vulnerabilities involves the RB1 tumor suppressor. While RB1 loss is common in aggressive cancers, Robert A. Jones and colleagues demonstrated in RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation that this loss forces cells to become hyper-dependent on mitochondrial protein translation. This discovery allowed the team to repurpose an existing antibiotic, tigecycline, to selectively kill cancer cells by "starving" their mitochondria.

Similarly, the presence or absence of RB1 dictates how a cell handles glucose. Research by Qin Wu and Wail Ba-Alawi in GLUT1 inhibition blocks growth of RB1-positive Triple Negative Breast Cancer shows that RB1-positive TNBC cells are uniquely vulnerable to the inhibition of the glucose transporter GLUT1. Without this transporter, these specific cells cannot meet their energy demands, whereas RB1-negative cells are able to switch to alternative fuel sources.

Mapping Kinase Addictions and Signaling Hijacks

Even without traditional receptors, cancer cells still rely on internal signaling cascades to communicate growth signals. Researchers are now using bioinformatics to identify "kinase addictions"—specific enzymes that the cancer cell cannot live without.

Karen A. Ryall and her team developed a framework to integrate drug sensitivity screens with genomic data, as detailed in An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer. They identified kinases like MAP4K4 and PRKD3 as critical nodes in the TNBC signaling network.

Other researchers are targeting the "molecular scissors" that release growth factors. Francesco Caiazza and Norma O’Donovan identified that inhibiting the enzyme ADAM-17 with a monoclonal antibody can stifle EGFR signaling in TNBC, effectively cutting off the growth signals at the source (Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells).

Repurposing the Pharmacopeia

Because developing new drugs is slow, a major facet of this research involves finding "off-target" effects of existing medications that hit these newly discovered vulnerabilities.

Reshaping the Immune Microenvironment

When the cancer cell itself is difficult to target, researchers look to the surrounding "soil." Receptor-negative cancers often create an immunosuppressive "fortress" that prevents the body's natural defenses from attacking.

Guangxin Li and Jiajia Hu demonstrated that while certain inhibitors can inadvertently strengthen this fortress, combining them with PD-1 blockade can "normalize" the tumor's blood vessels, allowing T-cells to infiltrate and destroy the tumor (Everolimus combined with PD-1 blockade inhibits progression of triple-negative breast cancer).

Furthermore, the spatial arrangement of immune cells matters. José Villacorta Hidalgo discovered that in TNBC subtypes with better prognoses, $\gamma\delta$ T-cells are in direct contact with tumor cells, whereas in more aggressive types, they are sequestered in the surrounding tissue (Histological Analysis of γδ T Lymphocytes Infiltrating Human Triple-Negative Breast Carcinomas). Understanding these spatial dynamics is key to developing immunotherapies for "cold" tumors that lack standard markers like PD-L1.

Papers in this version

Showing 60 of 97 papers.

History & citationVersion 2 · 2026-10-04

Current · Permanent link

  1. Version 2 (latest) · 2026-10-04 · 53 papers
  2. Version 1 · 2026-10-04 · 97 papers
Cite this direction

Latest version (a living page):

@misc{lacuna_targeted_therapy_limitations_44624635,
  title = {targeted therapy limitations},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/targeted-therapy-limitations/rdr_44624635eb6645929a355341f3583a6a},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-21},
}

This exact version (version 1, frozen text):

@misc{lacuna_identifying_therapeutic_targets_in_recep_44624635_v1,
  title = {Identifying Therapeutic Targets in Receptor-Negative Cancers},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/identifying-therapeutic-targets-in-receptor-negative-cancers/rdr_44624635eb6645929a355341f3583a6a/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-21},
}